Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Follow-Up Questions
Newron Pharmaceuticals SpA의 CEO는 누구입니까?
Prof. Stefan Weber은 2005부터 회사에 합류한 Newron Pharmaceuticals SpA의 Chief Executive Officer입니다.
NWPHF 주식의 가격 성능은 어떻습니까?
NWPHF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Newron Pharmaceuticals SpA의 주요 사업 주제나 업종은 무엇입니까?
Newron Pharmaceuticals SpA은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Newron Pharmaceuticals SpA의 시가총액은 얼마입니까?
Newron Pharmaceuticals SpA의 현재 시가총액은 $0입니다
Newron Pharmaceuticals SpA는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Newron Pharmaceuticals SpA에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
